Although EGFR-TKIs have an excellent initial clinical therapeutic effect, the intrinsic resistance and acquired resistance to EGFR-TKIs pose a major barrier to the widespread use of EGFR-TKIs in clinical lung cancer treatment. Here, EGFR is linked to lung carcinoma.